140 J . Org. Chem., Vol. 66, No. 1, 2001
Kobayashi et al.
4.99 (1H, m, H-18), 5.46 (1H, t, J ) 5.3 Hz, H-12), 7.43 (3H,
m), and 7.68 (2H, m); FABMS m/z 639 (M+H)+; HRFABMS
m/z 639.3507 [calcd for C35H49O7F3 (M + H)+, 639.3508].
H-12), 7.39 (3H, m), and 7.57 (2H, m); FABMS m/z 639 (M +
H)+; HRFABMS m/z 639.3512 [calcd for C35H49O7F3 (M + H)+,
639.3508].
Oxid a tive Degr a d a tion of Am p h id in olid e T4 (4). Am-
phidinolide T4 (4, 0.2 mg) was treated with LiAlH4, NaIO4,
NaBH4, and (R)-(-)-MTPACl by the same procedure as
described above to afford compounds 6a (0.07 mg, tR 16.0 min)
and 7a (0.03 mg, tR 13.6 min). 6a : 1H NMR (CDCl3) δ 0.86
(3H, d, J ) 7.0 Hz, H3-23), 0.91 (3H, d, J ) 6.7 Hz, H3-22),
1.1-1.45 (8H, m, H2-3, H2-4, H2-5, and H2-6), 1.69 (2H, m, H2-
9), 1.78-1.93 (3H, m, H-2 and H2-11), 2.19 (1H, m, H-8), 3.54
(6H, s, 2 × OCH3), 3.79 (1H, m, H-7), 4.05 (1H, m, H-10), 4.06
(1H, dd, J ) 6.7, 10.7 Hz, H-1), 4.23 (1H, dd, J ) 5.6, 10.7 Hz,
H-1), 4.41 (2H, t, J ) 6.8 Hz, H2-12), 7.35-4.43 (6H, m, Ph),
and 7.48-7.54 (4H, m, Ph); FABMS m/z 699 (M + Na)+;
HRFABMS m/z 699.2754 [calcd for C34H42O7F6Na (M + Na)+,
699.2732]. 7a : 1H NMR (CDCl3) δ 0.88 (3H, d, J ) 6.3 Hz,
H3-24), 0.90 (3H, t, J ) 7.5 Hz, H3-21), 1.28-1.40 (2H, m, H2-
20), 1.56 (1H, m, H-19), 1.62 (1H, m, H-19), 1.84 (1H, m, H-15),
1.97-2.05 (1H, m, H-14, H-15), 2.17 (1H, dd, J ) 6.0, 14.2 Hz,
H-17), 2.28 (1H, dd, J ) 7.6, 14.2 Hz, H-17), 3.52 (3H, s, OCH3),
3.54 (3H, s, OCH3), 4.09 (1H, dd, J ) 5.8, 10.2 Hz, H-13), 4.13
(1H, dd, J ) 4.3, 10.2 Hz, H-13), 4.68 (1H, s, H-25), 4.75 (1H,
s, H-25), 5.20 (1H, m, H-18), 7.35-4.43 (6H, m, Ph), and 7.48-
7.54 (4H, m, Ph); FABMS m/z 641 (M + Na)+; HRFABMS m/z
641.2284 [calcd for C31H36O6F6Na (M + Na)+, 641.2314].
Bis-(S)-(-)-MTP A Ester (9a ) of Am p h id in olid e T2 (2).
Amphidinolide T2 (2, 0.1 mg) was treated with (R)-(-)-
MTPACl (0.3 µL) by the same procedure as described above
to afford the bis-(S)-(-)-MTPA ester (9a , 0.2 mg) of 4. 9a : a
Oxid a tive Degr a d a tion of Am p h id in olid e T3 (3). Am-
phidinolide T3 (3, 0.2 mg) was dissolved in THF (20 µL) and
treated with LiAlH4 (0.8 mg) at room temperature for 1 h. The
reaction mixture was partitioned between EtOAc (200 µL ×
3) and 1 M phosphate buffer (100 µL). The organic phase was
evaporated in vacuo to afford a crude residue. To a solution of
the residue in THF/1 M phosphate buffer (1:1, 50 µL) was
added NaIO4 (0.5 mg), and the mixture was stirred at room
temperature for 30 min. After evaporation, the reaction
mixture was extracted with EtOAc (200 µL), and the extract
was evaporated in vacuo. To a solution of the residue in EtOH
(50 µL) was added NaBH4 (0.3 mg) at 0 °C, and stirring was
continued for 30 min. The mixture was evaporated and then
partitioned between EtOAc (200 µL × 3) and 1 M phosphate
buffer (100 µL). The organic phase was evaporated, and the
residue was dissolved in 0.1% DMAP solution in CH2Cl2 (50
µL). To the mixture were added Et3N (2 µL) and (R)-(-)-
MTPACl (1 µL), and stirring was continued at room temper-
ature for 2 h. After addition of N,N-dimethyl-1,3-propanedi-
amine (3 µL), the solvent was evaporated in vacuo. The residue
was subjected to silica gel column chromatography (hexane/
EtOAc, 8:1) followed by C18 HPLC (Wakosil-II 5C18 RS, Wako
Pure Chemical Ind., Ltd., 4.6 × 250 mm; eluent CH3CN/H2O,
90:10; flow rate, 1.0 mL/min; UV detection at 230 nm) to give
compounds 6a (0.08 mg, tR 16.0 min) and 7a (0.05 mg, tR 13.6
min). 6a : 1H NMR (CDCl3) δ 0.86 (3H, d, J ) 7.0 Hz, H3-23),
0.91 (3H, d, J ) 6.7 Hz, H3-22), 1.1-1.45 (8H, m, H2-3, H2-4,
H2-5, and H2-6), 1.69 (2H, m, H2-9), 1.78-1.93 (3H, m, H-2
and H2-11), 2.19 (1H, m, H-8), 3.54 (6H, s, 2 × OCH3), 3.79
(1H, m, H-7), 4.05 (1H, m, H-10), 4.06 (1H, dd, J ) 6.7, 10.7
Hz, H-1), 4.23 (1H, dd, J ) 5.6, 10.7 Hz, H-1), 4.41 (2H, t, J )
6.9 Hz, H2-12), 7.35-4.43 (6H, m, Ph), and 7.48-7.54 (4H, m,
Ph); FABMS m/z 699 (M +Na)+; HRFABMS m/z 699.2720
[calcd for C34H42O7F6Na (M + Na)+, 699.2732]. 7a : 1H NMR
(CDCl3) δ 0.88 (3H, d, J ) 6.3 Hz, H3-24), 0.90 (3H, t, J ) 7.5
Hz, H3-21), 1.28-1.40 (2H, m, H2-20), 1.56 (1H, m, H-19), 1.62
(1H, m, H-19), 1.84 (1H, m, H-15), 1.97-2.05 (1H, m, H-14
and H-15), 2.17 (1H, dd, J ) 6.0, 14.2 Hz, H-17), 2.28 (1H, dd,
J ) 7.6, 14.2 Hz, H-17), 3.52 (3H, s, OCH3), 3.54 (3H, s, OCH3),
4.09 (1H, dd, J ) 5.8, 10.2 Hz, H-13), 4.13 (1H, dd, J ) 4.3,
10.2 Hz, H-13), 4.68 (1H, s, H-25), 4.75 (1H, s, H-25), 5.20 (1H,
m, H-18), 7.35-4.43 (6H, m, Ph), and 7.48-7.54 (4H, m, Ph);
FABMS m/z 641 (M + Na)+; HRFABMS m/z 641.2308 [calcd
for C31H36O6F6Na (M + Na)+, 641.2314].
1
colorless oil; H NMR (CDCl3) δ 0.87 (3H, d, J ) 7.0 Hz, H3-
24), 0.92 (3H, J ) 6.7 Hz, H3-25), 1.12 (3H, d, J ) 6.9 Hz,
H3-23), 1.26 (3H, d, J ) 6.1 Hz, H3-22), 1.25-1.75 (14 H), 1.88
(1H, dd, J ) 10.9, 14.5 Hz, H-15), 2.06 (1H, dt, 14.6 and 4.4
Hz, H-11), 2.10-2.15 (2H, m, H-11 and H-17), 2.22 (1H, m,
H-8), 2.36 (1H, dd, J ) 6.9, 13.9 Hz, H-17), 2.41 (1H, m, H-2),
2.58 (1H, br.d, J ) 14.5 Hz, H-15), 3.10 (1H, m, H-14), 3.53
(3H, s, OCH3), 3.56 (3H, s, OCH3), 3.85 (1H, m, H-7), 4.07 (1H,
m, H-10), 4.82 (1H, s, H-25), 4.88 (1H, s, H-25), 4.95 (1H, m,
H-18), 5.11 (1H, m, H-21), 5.50 (1H, t, J ) 5.2 Hz, H-12), 7.38-
7.43 (6H, m), 7.51 (2H, m), and 7.59 (2H, m); ESIMS m/z 907
(M + Na)+; HRESIMS m/z 907.3822 [calcd for C46H58O10F6Na
(M + Na)+, 907.3832].
Bis-(R)-(+)-MTP A Ester (9b) of Am p h id in olid e T2 (2).
Amphidinolide T2 (2, 0.1 mg) was treated with (S)-(+)-MTPACl
(0.3 µL) by the same procedure as described above to afford
the bis-(R)-(+)-MTPA ester (9b, 0.1 mg) of 4. 9b: a colorless
1
oil; H NMR (CDCl3) δ 0.80 (3H, d, J ) 7.0 Hz, H3-24), 0.97
(S)-(-)-MTP A Ester (8a ) of Am p h id in olid e T4 (4).
Amphidinolide T4 (4, 0.2 mg) was treated with (R)-(-)-
MTPACl (0.5 µL) by the same procedure as described above
(3H, d, J ) 6.6 Hz, H3-25), 1.12 (3H, d, J ) 6.9 Hz, H3-23),
1.34 (3H, d, J ) 6.3 Hz, H3-22), 1.23-1.60 (10 H), 1.67 (1H,
m, H-20), 1.87 (1H, m, H-15), 1.97 (1H, dt, J ) 15.5, 6.0 Hz,
H-11), 2.01-2.11 (3H, m, H-8, H-11, and H-17), 2.34 (1H, dd,
J ) 6.5, 14.0 Hz, H-17), 2.41 (1H, m, H-2), 2.65 (1H, br.d, J )
14.3 Hz, H-15), 3.07 (1H, m, H-14), 3.55 (3H, s, OCH3), 3.68
(3H, s, OCH3), 3.79 (1H, m, H-7), 4.06 (1H, m, H-10), 4.84 (1H,
s, H-25), 4.86 (1H, s, H-25), 4.93 (1H, m, H-18), 5.13 (1H, m,
H-21), 5.43 (1H, t, J ) 5.4 Hz, H-12), 7.36-7.45 (6H, m), 7.52
(2H, m), and 7.67 (2H, m); ESIMS m/z 907 (M + Na)+;
HRESIMS m/z 907.3821 [calcd for C46H58O10F6Na (M + Na)+,
907.3832].
to afford the (S)-(-)-MTPA ester (8a , 0.2 mg) of 4. 8a :
a
1
colorless oil; H NMR (CDCl3) δ 0.78 (3H, d, J ) 7.1 Hz, H3-
23), 0.90 (3H, t, J ) 7.3 Hz, H3-21), 1.17 (3H, d, J ) 7.0 Hz,
H3-22), 1.19 (3H, d, J ) 6.8 Hz, H3-24), 1.25-1.65 (14 H), 1.73
(1H, m, H-11), 1.92 (1H, m, H-11), 2.08 (1H, m, H-15), 2.12
(1H, m, H-8), 2.17 (1H, m, H-17), 2.37 (1H, dd, J ) 5.1, 13.5
Hz, H-17), 2.43 (1H, m, H-2), 2.47 (1H, m, H-15), 3.13 (1H, m,
H-14), 3.63 (3H, s, OCH3), 3.80 (1H, m, H-7), 3.96 (1H, m,
H-10), 4.90 (1H, s, H-25), 4.91 (1H, s, H-25), 4.92 (1H, m, H-18),
5.49 (1H, brd, J ) 8.6 Hz, H-12), 7.42 (3H, m), and 7.65 (2H,
m); FABMS m/z 639 (M + H)+; HRFABMS m/z 639.3523 [calcd
for C35H49O7F3 (M + H)+, 639.3508].
Oxid a tive Degr a d a tion of Am p h id in olid e T2 (2). Am-
phidinolide T2 (2, 0.2 mg) was dissolved in THF (30 µL) and
treated with LiAlH4 (1.0 mg) at room temperature for 1 h. The
reaction mixture was partitioned between EtOAc (200 µL ×
3) and 1M phosphate buffer (100 µL). The organic phase was
evaporated in vacuo to afford a crude residue. To a solution of
the residue in THF/1 M phosphate buffer (1:1, 30 µL) was
added NaIO4 (0.2 mg), and the mixture was stirred at room
temperature for 1 h. After evaporation, the reaction mixture
was extracted with EtOAc (200 µL) and the extract was
evaporated in vacuo. To a solution of the residue in EtOH (30
µL) was added NaBH4 (0.2 mg) at 0 °C, and stirring was
continued for 30 min. After addition of 1M phosphate buffer
(100 µL), the mixture was partitioned between EtOAc (200 µL
× 3). The organic phase was evaporated to give the residue
(R)-(+)-MTP A Ester (8b) of Am p h id in olid e T4 (4).
Amphidinolide T4 (4, 0.2 mg) was treated with (S)-(+)-MTPACl
(0.5 µL) by the same procedure as described above to afford
the (R)-(+)-MTPA ester (8b, 0.2 mg) of 4. 8b: a colorless oil;
1H NMR (CDCl3) δ 0.85 (3H, d, J ) 7.0 Hz, H3-23), 0.90 (3H,
t, J ) 7.3 Hz, H3-21), 1.17 (3H, d, J ) 7.0 Hz, H3-22), 1.17
(3H, d, J ) 6.8 Hz, H3-24), 1.25-1.65 (12 H), 1.70-1.82 (3H),
1.96 (1H, m, H-11), 2.06 (1H, dd, J ) 8.7, 13.5 Hz, H-15), 2.16
(1H, m, H-8), 2.17 (1H, m, H-17), 2.36 (1H, m, H-17), 2.43 (1H,
m, H-2), 2.46 (1H, brd, J ) 13.5 Hz, H-15), 3.12 (1H, m, H-14),
3.54 (3H, s, OCH3), 3.84 (1H, m, H-7), 4.19 (1H, m, H-10), 4.89
(2H, s, H2-25), 4.92 (1H, m, H-18), 5.52 (1H, t, J ) 5.3 Hz,